title: PET of αvbeta3-integrin and αvbeta5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time?
authors.affiliation: Technische Universität München Munich, Germany. ambros.beer@tum.de
authors.forename: Ambros J
authors.initials: AJ
authors.lastname: Beer
authors.forename: Markus
authors.initials: M
authors.lastname: Schwaiger
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D045744:Cell Line, Tumor; D005909:Glioblastoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D010455:Peptides / Q000493:pharmacokinetics*; D011092:Polyethylene Glycols / Q000493:pharmacokinetics*; D011758:Pyrroles / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D019030:Receptors, Vitronectin / Q000378:metabolism*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D000077210:Sunitinib
chemical_list: C530281:AH 111585; D020533:Angiogenesis Inhibitors; D007211:Indoles; D039302:Integrin alphaVbeta3; D010455:Peptides; D011758:Pyrroles; D019275:Radiopharmaceuticals; D019030:Receptors, Vitronectin; C064660:integrin alphaVbeta5; D011092:Polyethylene Glycols; D000077210:Sunitinib